HK1094650A1 - The use of fumaric acid derivatives in the manufacture of a medicament for treating asthma and chronic obstructive pulmonary diseases - Google Patents

The use of fumaric acid derivatives in the manufacture of a medicament for treating asthma and chronic obstructive pulmonary diseases

Info

Publication number
HK1094650A1
HK1094650A1 HK07101740.4A HK07101740A HK1094650A1 HK 1094650 A1 HK1094650 A1 HK 1094650A1 HK 07101740 A HK07101740 A HK 07101740A HK 1094650 A1 HK1094650 A1 HK 1094650A1
Authority
HK
Hong Kong
Prior art keywords
fumaric acid
acid derivatives
medicament
manufacture
chronic obstructive
Prior art date
Application number
HK07101740.4A
Inventor
Rajendra Kumar Joshi
Hans-Peter Strebel
Christian Zaugg
Michael Tamm
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2004/009835 external-priority patent/WO2005023241A1/en
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of HK1094650A1 publication Critical patent/HK1094650A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

FIELD: medicine, pharmaceutics. ^ SUBSTANCE: what is presented is using fumaric acid derivatives specified in a group consisting of dialkylfumarates, monoalkylhydrofumarates, fumaric acid monoalkyl ester salts, fumaric acid monoamides, fumaric acid monoamide salts, fumaric acid diamides, monoalkyl monoamido fumarates, carbocyclic and oxacarbocyclic oligomers of these compounds or their mixtures for preparing a drug for treatment or prevention of cardiac failure, particularly left-ventricular failure, myocardial infarction and angina. ^ EFFECT: dimethylfumarate has appeared to reduce considerably an area of infarction caused by ischemia followed by reperfusion. ^ 19 cl, 4 dwg, 7 ex
HK07101740.4A 2003-09-09 2007-02-14 The use of fumaric acid derivatives in the manufacture of a medicament for treating asthma and chronic obstructive pulmonary diseases HK1094650A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10341530 2003-09-09
DE10360869A DE10360869A1 (en) 2003-09-09 2003-12-23 Use of fumaric acid derivatives for the treatment of heart failure, hyperkeratosis and asthma
PCT/EP2004/009835 WO2005023241A1 (en) 2003-09-09 2004-09-03 The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma

Publications (1)

Publication Number Publication Date
HK1094650A1 true HK1094650A1 (en) 2007-04-04

Family

ID=34258515

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07101740.4A HK1094650A1 (en) 2003-09-09 2007-02-14 The use of fumaric acid derivatives in the manufacture of a medicament for treating asthma and chronic obstructive pulmonary diseases

Country Status (12)

Country Link
JP (3) JP2008529959A (en)
CN (2) CN1829505B (en)
AT (1) ATE447946T1 (en)
CY (1) CY1107849T1 (en)
DE (2) DE10360869A1 (en)
HK (1) HK1094650A1 (en)
IL (1) IL171987A (en)
NZ (1) NZ543708A (en)
PT (1) PT1663197E (en)
RS (1) RS51881B (en)
RU (2) RU2459621C2 (en)
ZA (1) ZA200601985B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334378B1 (en) 2008-08-19 2014-04-09 XenoPort, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
HK1252751A1 (en) * 2009-01-09 2019-05-31 Fwp Ip Aps Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
RU2743637C2 (en) * 2009-01-09 2021-02-20 Фвп Ип Апс Pharmaceutical composition containing one or more esters of fumaric acid in a decomposable matrix
EP2782561A1 (en) * 2011-11-24 2014-10-01 Synthon BV Controlled release particles comprising dimethyl fumarate
AU2013203445C1 (en) * 2012-02-07 2017-04-20 Biogen Ma Inc. Pharmaceutical compositions containing dimethyl fumarate
EP2887933A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
KR101379427B1 (en) * 2013-02-13 2014-03-28 경북대학교병원 Composition for preventing or treating renal fibrosis comprising dimethylfumarate
WO2014160633A1 (en) 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
US9302977B2 (en) 2013-06-07 2016-04-05 Xenoport, Inc. Method of making monomethyl fumarate
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US4959389A (en) * 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
DE19721099C2 (en) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Use of fumaric acid derivatives
DE19814358C2 (en) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Use of alkyl hydrogen fumarates for the treatment of psoriasis, psoriatic arthritis, neurodermatitis and enteritis regionalis Crohn
DE19839566C2 (en) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Use of fumaric acid derivatives in transplant medicine
DE19853487A1 (en) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Use of dialkyl fumarate for treating transplant rejection and autoimmune disease
PL392750A1 (en) * 2001-01-12 2011-05-23 Fumapharm Ag Fumaric acid amides
DE10101307A1 (en) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumaric acid derivatives as NF-kappaB inhibitor
RU2189813C1 (en) * 2001-06-01 2002-09-27 Российский научно-исследовательский институт гематологии и трансфузиологии Antihypoxic medicinal agent
DE10217314A1 (en) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclic and oxacarboncyclic fumaric acid oligomers

Also Published As

Publication number Publication date
CN102058574A (en) 2011-05-18
DE602004024143D1 (en) 2009-12-24
DE10360869A1 (en) 2005-04-07
JP2010070563A (en) 2010-04-02
CN102058574B (en) 2013-02-13
NZ543708A (en) 2008-11-28
RU2007138216A (en) 2009-04-20
RS51881B (en) 2012-02-29
RS20050948A (en) 2008-04-04
JP2008529959A (en) 2008-08-07
CN1829505A (en) 2006-09-06
IL171987A0 (en) 2006-04-10
IL171987A (en) 2010-12-30
JP2015155480A (en) 2015-08-27
ATE447946T1 (en) 2009-11-15
ZA200601985B (en) 2007-05-30
CN1829505B (en) 2010-11-10
RU2012115860A (en) 2013-10-27
PT1663197E (en) 2007-12-26
CY1107849T1 (en) 2013-06-19
JP5784877B2 (en) 2015-09-24
RU2459621C2 (en) 2012-08-27

Similar Documents

Publication Publication Date Title
HK1094650A1 (en) The use of fumaric acid derivatives in the manufacture of a medicament for treating asthma and chronic obstructive pulmonary diseases
JP4966659B2 (en) Dual alanylaminopeptidase and dipeptidylpeptidase IV inhibitors that functionally affect different cells and treat immune diseases, inflammatory diseases, neurological diseases, and other diseases
CA2414967A1 (en) Valproic acid and derivatives thereof as histone deacetylase inhibitors
EP1592665A4 (en) Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
DK1154993T3 (en) Thioamide derivatives
JP6262225B2 (en) Oxabicycloheptanes and oxabicycloheptanes for the treatment of reperfusion injury
EA201270144A1 (en) COMBINED THERAPY FOR TREATMENT OF DIABETES
MX2010002353A (en) Heterocyclic amides useful for the treatment of cancer and psoriasis.
SE0104340D0 (en) New compounds
DE60016191D1 (en) CYCLOOXYGENASE-2 INHIBITORY COMPOSITIONS WITH FAST ACTION INTRUSION
PL1663197T3 (en) The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
ME01310B (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
TNSN04136A1 (en) Aza-arylpiperazines
HRP20100577T1 (en) Use of agomelatine to obtain a medication aimed at treating generalised anxiety disorder
NZ594184A (en) Skin treatment
ATE367387T1 (en) USE OF OXINDOL DERIVATIVES FOR THE TREATMENT OF DEMENTIA-RELATED DISEASES, ALZHEIMER'S DISEASE AND GLYCOGEN SYNTHASE KINASE-3-ASSOCIATED CONDITIONS
ECSP045469A (en) THE USE OF REPLACED CYANOPIRROLIDINS AND COMBINATION PREPARATIONS CONTAINING THEM TO TREAT HYPERLIPIDEMIA AND ASSOCIATED DISEASES
HUP0103112A2 (en) Use of glycogen phosphorylase inhibitors to inhibit tumor growth
CN108863892B (en) Gallic acid methyl ester analogue containing amide structure and application thereof
ES2339021T3 (en) USEFUL ALFA-AMINOAMIDE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS.
JP6945618B2 (en) Amide derivative of polycafe oil quinic acid, its production method and its use
CA2362833A1 (en) Phenylalaninol derivatives
ATE295845T1 (en) PRUCALOPRIDE-N-OXIDE
TW200500342A (en) 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxypyridin-3-yl)propyl]benz-amide, its use as a medicament, and pharmaceutical preparations comprising it
DE602006016168D1 (en) 1,3,5-triazepine-diones for the treatment of malaria

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160903